Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Average Rating of "Buy" from Analysts

Key Points

• Compass Therapeutics, Inc. has received an average analyst rating of "Buy", with nine analysts upgrading the stock and one providing a strong buy rating.
• The average one-year target price set by analysts for Compass Therapeutics is $12.67, with individual price targets ranging significantly from $9.00 to $32.00.
• Hedge funds and institutional investors hold 68.43% of Compass Therapeutics' stock, indicating strong institutional interest in the company.

Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) has been given an average rating of "Buy" by the ten analysts that are covering the firm, Marketbeat.com reports. Nine analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $12.6667.

CMPX has been the subject of several research analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $24.00 price objective on shares of Compass Therapeutics in a report on Monday, April 21st. Raymond James Financial raised Compass Therapeutics to an "outperform" rating and set a $9.00 price target for the company in a report on Tuesday, July 1st. Guggenheim cut their price target on Compass Therapeutics from $12.00 to $10.00 and set a "buy" rating for the company in a report on Friday, May 9th. Finally, D. Boral Capital reissued a "buy" rating and set a $32.00 price target on shares of Compass Therapeutics in a report on Monday, April 28th.

Hedge Funds Weigh In On Compass Therapeutics

Large investors have recently made changes to their positions in the business. Tower Research Capital LLC TRC lifted its position in shares of Compass Therapeutics by 298.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company's stock valued at $25,000 after acquiring an additional 12,917 shares in the last quarter. BNP Paribas Financial Markets purchased a new position in shares of Compass Therapeutics in the fourth quarter valued at about $27,000. Mariner LLC purchased a new position in shares of Compass Therapeutics in the fourth quarter valued at about $30,000. Strs Ohio purchased a new position in shares of Compass Therapeutics in the first quarter valued at about $34,000. Finally, Squarepoint Ops LLC purchased a new position in shares of Compass Therapeutics in the fourth quarter valued at about $35,000. 68.43% of the stock is currently owned by hedge funds and other institutional investors.

Compass Therapeutics Price Performance

Shares of CMPX opened at $2.85 on Tuesday. Compass Therapeutics has a one year low of $0.87 and a one year high of $4.08. The firm has a market capitalization of $394.11 million, a P/E ratio of -6.95 and a beta of 1.49. The business has a fifty day moving average of $2.66 and a 200 day moving average of $2.49.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.12) EPS for the quarter, hitting the consensus estimate of ($0.12). Analysts expect that Compass Therapeutics will post -0.36 EPS for the current fiscal year.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.